logo
logo

Chase Therapeutics Announces $20 Million Series B Financing To Advance Clinical Trials In Parkinson’S Disease And Major Depressive Disorder

Oct 20, 2021•over 3 years ago

Amount Raised

$20 Million

Round Type

series b

Description

Chase Therapeutics Corporation, a Washington, DC based clinical stage pharmaceutical company, today announced the completion of a milestone-based $20M Series B financing led by Chinalink Asia Holdings of Hong Kong. This new round builds on the earlier financings from Brain Trust Accelerator Fund II of Burlingame, CA, and the Rise of the Rest Fund and Makana Holdings of Washington, DC. The company also announced that Javier Romero, Chairman and CEO of Chinalink, will join the Board of Directors.

Company Information

Company

Chase Therapeutics

About

Chase Therapeutics Corporation, since its inception in 2016, has pioneered the discovery and development of needed pharmaceuticals for brain disease. The company focuses on the rapid translation of therapeutic breakthroughs in neurosciences research that may help prevent and potentially cure central nervous system dysfunction. Lead drugs in its pipeline include CTC-413 for the palliative and neuroprotective treatment of Parkinson’s Disease and CTC-501 for Major Depressive Disorder. Both drugs, along with a companion diagnostic for Parkinson’s disease, are now entering Phase 3 development. Chase Therapeutics stands committed to improving the lives of all those afflicted by neuropsychiatric disease. For more information, please go to http://www.chasetherapeutics.com/

Funding Insights

Based on industry data
Tech investment trends
83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech